1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Fatty Acid Synthase (FASN)

Fatty Acid Synthase (FASN)

Fatty Acid Synthase (FASN) is a multifunctional homodimeric enzyme protein, and it is the major enzyme required for the anabolic conversion of dietary carbohydrates to fatty acids. Fatty acid synthase catalyzes the conversion of acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids.

Human fatty acid synthase is a large homodimeric multifunctional enzyme that synthesizes palmitic acid. The unique carboxyl terminal thioesterase domain of fatty acid synthase hydrolyzes the growing fatty acid chain and plays a critical role in regulating the chain length of fatty acid released. Also, the up-regulation of human fatty acid synthase in a variety of cancer makes the thioesterase a candidate target for therapeutic treatment.

Fatty Acid Synthase (FASN) Related Products (31):

Cat. No. Product Name Effect Purity
  • HY-12364
    C75 Inhibitor 99.91%
    C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM. C75 is a potent CPT1A activator.
  • HY-14452
    Fatostatin Inhibitor 98.20%
    Fatostatin (125B11), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. Fatostatin possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.
  • HY-B0218
    Orlistat Inhibitor ≥98.0%
    Orlistat is a lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats.
  • HY-N0083
    Betulin Inhibitor ≥98.0%
    Betulin (Trochol), is a sterol regulatory element-binding protein (SREBP) inhibitor with an IC50 of 14.5 μM in K562 cell line.
  • HY-13447A
    PF429242 dihydrochloride Inhibitor 98.08%
    PF429242 dihydrochloride is a reversible and competitive SREBP site 1 protease (S1P) inhibitor with an IC50 of 175 nM.
  • HY-16100
    BI 99179 Inhibitor 99.78%
    BI 99179 is a potent and selective type I fatty acid synthase (FAS) inhibitor with an IC50 of 79 nM. BI 99179 is a tool compound suitable for the in vivo validation of FAS as a target for lipid metabolism related diseases. BI 99179 exhibits significant exposure (both peripheral and central) upon oral administration in rats.
  • HY-124628
    IPI-9119 Inhibitor
    IPI-9119 is an orally active, selective and irreversible FASN inhibitor with an IC50 of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse models.
  • HY-U00436
    FASN-IN-3 Inhibitor 98.17%
    FASN-IN-3 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A.
  • HY-120394
    TVB-3166 Inhibitor 99.55%
    TVB-3166 is an orally-available, reversible, and selective fatty acid synthase (FASN) inhibitor with IC50s of 42 nM and 81 nM for biochemical FASN and cellular palmitate synthesis, respectively. TVB-3166 induces apoptosis, and inhibits in-vivo xenograft tumor growth.
  • HY-A0210
    Cerulenin Inhibitor ≥99.0%
    Cerulenin, the best known natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus.
  • HY-111551
    FT113 Inhibitor 99.18%
    FT113 is a potent and orally active fatty acid synthase (FASN) inhibitor, with an IC50 of 213 nM for full-length recombinant human FASN enzyme. In cell-based assay, FT113 blocks FASN activity in BT474 cells (IC50, 90 nM). FT113 shows anti-proliferative activity, and exhibits anti-cancer activity both in vitro and in vivo.
  • HY-N0288
    Lycorine Inhibitor ≥98.0%
    Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a Kd value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription. Lycorine is also a melanoma vasculogenic inhibitor. Lycorine can be used for the study of prostate cancer and metabolic diseases.
  • HY-12364A
    trans-C75 Inhibitor ≥98.0%
    trans-C75 ((±)-C75) is an enantiomer of C75. C75 is a synthetic fatty-acid synthase (FASN) inhibitor.
  • HY-120062
    TVB-3664 Inhibitor 99.66%
    TVB-3664 is an orally available, reversible, potent, selective and highly bioavailable fatty acid synthase (FASN) inhibitor, with IC50 values of 18 nM and 12 nM for human and mouse cell palmitate synthesis, respectively. TVB-3664 significantly reduces tubulin palmitoylation and mRNA expression.
  • HY-112829
    FASN-IN-2 Inhibitor 99.69%
    FASN-IN-2 is a Fatty Acid Synthase (FASN) inhibitor extracted from patent WO2012122391A1, compound 152, has an IC50 of 0.052 μM and an EC50 of 0.072 μM.
  • HY-12648A
    FASN-IN-4 tosylate Inhibitor 98.63%
    FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase (FASN) extracted from patent WO 2012064642 A1, compound 29; has an IC50 of 10 nM.
  • HY-N2486
    Desoxyrhaponticin Inhibitor 99.80%
    Desoxyrhaponticin is a stilbene glycoside from the Tibetan nutritional food Rheum tanguticum Maxim. Desoxyrhaponticin is a Fatty acid synthase (FASN) inhibitor, and has apoptotic effect on human cancer cells.
  • HY-111777
    FASN-IN-1 Inhibitor 99.62%
    FASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56.
  • HY-N0082
    Praeruptorin B Inhibitor 99.95%
    Praeruptorin B is an inhibitor of sterol regulatory element-binding proteins (SREBPs).
  • HY-N0686
    Pseudoprotodioscin Inhibitor 98.76%
    Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.